Clin2
NCT07583953Possibly a fitNot yet recruiting

Personalized cancer vaccine added to standard cancer treatment

Solid Tumors

Part of Cancer clinical trials.

This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug called toripalimab. The vaccine is designed specifically for your tumor and may help your body's immune system fight cancer better after surgery or standard treatment.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
50 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • Age 18 or older
  • Good overall health and ability to care for yourself (ECOG score 0-1, meaning you can do most daily activities)
  • Expected to live at least 6 months
  • Have a solid tumor and are already receiving or planning to receive surgery and/or standard cancer treatment
  • Organs working well enough to tolerate the study drugs
  • Women: not pregnant, willing to use birth control (but not progesterone-only types), and not breastfeeding for 90 days after treatment. Men: willing to use birth control if sexually active and could cause pregnancy.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07680582Recruiting· Early Phase 1
Personalized cancer vaccine after surgery for solid tumors

This trial tests a personalized vaccine designed to train your immune system to fight any remaining cancer cells after surgery or during standard therapy. It is for people with solid tumors who are stable and have no signs of disease getting worse.

Shanghai, Shanghai Municipality
NCT07683832Not yet recruiting· Early Phase 1
Personalized cancer vaccine with toripalimab for resected NSCLC

This trial tests a personalized cancer vaccine, alone or with toripalimab (a drug that helps your immune system fight cancer), in people with non-small cell lung cancer (NSCLC) that was removed by surgery. It aims to see if the vaccine is safe and could help prevent the cancer from coming back.

NCT06088004Recruiting· Phase 1/Phase 2
ABO2011 for advanced solid tumors (phase 1/2)

This trial tests a new investigational drug called ABO2011, which is injected directly into tumors. It is for people with advanced solid tumors that have not responded to previous treatments. The goal is to see if the drug is safe and can help shrink or slow tumor growth.

Beijing
NCT06682117Recruiting
A study of a personalized vaccine for advanced solid tumors

This trial tests a personalized vaccine made from your own cells to help your immune system attack tumor-specific targets. It may be an option if standard treatments have stopped working or caused side effects you can't tolerate.

Shanghai, Shanghai Municipality
NCT06195293Recruiting· Phase 1
Personalized cancer vaccine for advanced solid tumors

This trial tests a personalized vaccine made from unique markers on your tumor cells (called neoantigens). The goal is to help your immune system fight the cancer more effectively. It is for people with advanced solid tumors who have not had gene therapy and are otherwise relatively healthy.

Guangzhou
NCT06878612Recruiting· Phase 1
Personalized tumor cell vaccine for advanced solid tumors

This trial tests a new vaccine made from your own tumor cells to see if it can help your immune system fight the cancer. It is for people with advanced solid tumors that have not responded to other treatments.

Chengdu, Sichuan

Hear when a new Solid Tumors trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.